MeSH D012170 - retinal vein occlusion
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Coherus BioSciences | Ranibizumab | Cimerli |  | 2022-08-02 | $147.408 M | Q2/23-Q1/24 |
| Genentech | Ranibizumab | Lucentis |  | 2006-06-30 |  |  |
| Ranibizumab | Susvimo |  | 2021-10-22 |  |  | |
| Midas Pharma | Ranibizumab | Ranivisio |  | 2022-08-25 |  |  |
| Novartis | Ranibizumab | Lucentis |  | 2007-01-22 | $1,848 M | Q2/20-Q2/23 |
| Samsung Bioepis | Ranibizumab | Byooviz |  | 2021-09-17 |  |  |
| Stada Arzneimittel | Ranibizumab | Ximluci |  | 2022-11-09 |  |  |
| Viatris | Aflibercept | Yesafili |  | 2023-09-15 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
50%9/18
Phase 2
68%17/25
Phase 3
45%13/29
Approved: 1Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use